blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3149480

EP3149480 - RISK-STRATIFICATION OF B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  17.09.2021
Database last updated on 09.04.2026
FormerThe patent has been granted
Status updated on  23.11.2018
FormerGrant of patent is intended
Status updated on  19.07.2018
FormerExamination is in progress
Status updated on  03.11.2017
FormerRequest for examination was made
Status updated on  03.03.2017
FormerThe international publication has been made
Status updated on  21.12.2016
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Amgen Research (Munich) GmbH
Staffelseestrasse 2
81477 München / DE
For all designated states
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, California 91320-1799 / US
[2017/14]
Inventor(s)01 / ZUGMAIER, Gerhard
c/o Amgen Research (Munich) GmbH
Staffelseestr. 2
81477 Munich / DE
02 / KUFER, Peter
c/o Amgen Research (Munich) GmbH
Staffelseestr. 2
81477 Munich / DE
03 / ALEKAR, Shilpa
One Amgen Center Drive
Thousand Oaks California 91320-1799 / US
 [2017/14]
Representative(s)Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB
Ganghoferstraße 68 B
80339 München / DE
[2018/52]
Former [2017/14]Schiweck, Weinzierl & Koch Patentanwälte Partnerschaft mbB
Landsberger Straße 98
80339 München / DE
Application number, filing date15727072.920.05.2015
[2017/14]
WO2015IB53705
Priority number, dateUS201462005560P30.05.2014         Original published format: US 201462005560 P
[2017/14]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015181683
Date:03.12.2015
Language:EN
[2015/48]
Type: A1 Application with search report 
No.:EP3149480
Date:05.04.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 03.12.2015 takes the place of the publication of the European patent application.
[2017/14]
Type: B1 Patent specification 
No.:EP3149480
Date:26.12.2018
Language:EN
[2018/52]
Search report(s)International search report - published on:EP03.12.2015
ClassificationIPC:G01N33/574
[2017/14]
CPC:
G01N33/57505 (EP,US); A61K35/17 (EP,US); A61K38/1774 (EP,US);
A61P25/00 (EP); C07K16/2803 (US); C07K16/2809 (US);
G01N33/5091 (EP,US); A61K2035/124 (US); C07K2317/31 (US);
C07K2317/622 (US); G01N2333/70503 (US); G01N2800/50 (EP,US);
G01N2800/52 (EP,US); G01N2800/56 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/14]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:RISIKOSTRATIFIZIERUNG VON PATIENTEN MIT AKUTER LYMPHATISCHER B-VORLÄUFER-LEUKÄMIE[2017/14]
English:RISK-STRATIFICATION OF B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS[2017/14]
French:STRATIFICATION DU RISQUE POUR PATIENTS SOUFFRANT DE LEUCÉMIE AIGUË LYMPHOBLASTIQUE À PRÉCURSEURS B[2017/14]
Entry into regional phase20.12.2016National basic fee paid 
20.12.2016Designation fee(s) paid 
20.12.2016Examination fee paid 
Examination procedure20.12.2015Date on which the examining division has become responsible
20.12.2016Examination requested  [2017/14]
03.07.2017Amendment by applicant (claims and/or description)
03.11.2017Despatch of a communication from the examining division (Time limit: M04)
12.03.2018Reply to a communication from the examining division
27.03.2018Despatch of a communication from the examining division (Time limit: M02)
25.05.2018Reply to a communication from the examining division
20.07.2018Communication of intention to grant the patent
19.11.2018Fee for grant paid
19.11.2018Fee for publishing/printing paid
19.11.2018Receipt of the translation of the claim(s)
Divisional application(s)EP18213926.1  / EP3531133
EP23192350.9  / EP4303585
Opposition(s)Opponent(s)01  26.09.2019  01.10.2019  ADMISSIBLE
SANOFI
54 rue La Boétie
75008 Paris / FR
Opponent's representative
Ipsilon
11 rue Saint-Georges
75009 Paris / FR
 [N/P]
Former [2019/45]
Opponent(s)01  26.09.2019  01.10.2019  ADMISSIBLE
SANOFI
54 rue La Boétie
75008 Paris / FR
Opponent's representative
Nony
11 rue Saint-Georges
75009 Paris / FR
14.10.2019Invitation to proprietor to file observations on the notice of opposition
21.02.2020Reply of patent proprietor to notice(s) of opposition
04.05.2021Date of oral proceedings
04.05.2021Legal effect of revocation of patent [2021/42]
04.06.2021Despatch of minutes of oral proceedings
04.06.2021Despatch of communication that the patent will be revoked
Fees paidRenewal fee
10.05.2017Renewal fee patent year 03
11.05.2018Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL26.12.2018
HR26.12.2018
MK26.12.2018
RS26.12.2018
SM26.12.2018
NO26.03.2019
[2022/31]
Former [2019/37]AL26.12.2018
HR26.12.2018
RS26.12.2018
SM26.12.2018
NO26.03.2019
Former [2019/26]AL26.12.2018
HR26.12.2018
RS26.12.2018
NO26.03.2019
Former [2019/25]HR26.12.2018
RS26.12.2018
NO26.03.2019
Former [2019/23]HR26.12.2018
NO26.03.2019
Former [2019/20]NO26.03.2019
Cited inInternational search[XI]   "BACKGROUND INFORMATION FOR THE PEDIATRIC SUBCOMMITTEE OF THE ONCOLOGIC DRUGS ADVISORY COMMITTEE MEETING 04 DECEMBER 2012", 4 December 2012 (2012-12-04), XP055203294, Retrieved from the Internet [retrieved on 20150717] [X] 1,7,15 * the whole document * * In particular: pp. 4-6, executive summary; Fig. 1; Table 1; Appendix A. *[I] 2-6,8-14,16-28
 [A]   G. TALLEN ET AL: "Long-Term Outcome in Children With Relapsed Acute Lymphoblastic Leukemia After Time-Point and Site-of-Relapse Stratification and Intensified Short-Course Multidrug Chemotherapy: Results of Trial ALL-REZ BFM 90", JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 14, 12 April 2010 (2010-04-12), pages 2339 - 2347, XP055203293, ISSN: 0732-183X, DOI: 10.1200/JCO.2009.25.1983 [A] 1-28 * the whole document * * In particular: Title; Abstract; Patients and methods section. *

DOI:   http://dx.doi.org/10.1200/JCO.2009.25.1983
 [A]   DIRK NAGORSEN ET AL: "Blinatumomab: A historical perspective", PHARMACOLOGY & THERAPEUTICS, vol. 136, no. 3, 1 December 2012 (2012-12-01), pages 334 - 342, XP055112692, ISSN: 0163-7258, DOI: 10.1016/j.pharmthera.2012.07.013 [A] 1-28 * the whole document * * In particular: p. 340-341, items 9-11. *

DOI:   http://dx.doi.org/10.1016/j.pharmthera.2012.07.013
 [A]   VISSER J H ET AL: "Prognostic value of day 14 blast percentage and the absolute blast index in bone marrow of children with acute lymphoblastic leukemia", PEDIATRIC HEMATOLOGY AND ONCOLOGY, TAYLOR AND FRANCIS, GB, vol. 18, no. 3, 1 January 2001 (2001-01-01), pages 187 - 191, XP008177028, ISSN: 0888-0018, DOI: 10.1080/08880010151114804 [A] 1-28 * the whole document * * In particular: Title; Abstract; Methods section. *

DOI:   http://dx.doi.org/10.1080/08880010151114804
 [A]   JAN STARY ET AL: "Results of the Randomized I-BFM-SG Trial "Acute Lymphoblastic Leukemia Intercontinental-BFM 2002" in 5060 Children Diagnosed in 15 Countries on 3 Continents", 18 September 2011 (2011-09-18), pages 397 - 398, XP055203224, Retrieved from the Internet [retrieved on 20150717] [A] 1-28 * the whole document *
 [A]   G. BASSO ET AL: "Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow", JOURNAL OF CLINICAL ONCOLOGY, vol. 27, no. 31, 5 October 2009 (2009-10-05), pages 5168 - 5174, XP055203226, ISSN: 0732-183X, DOI: 10.1200/JCO.2008.20.8934 [A] 1-28 * the whole document * * In particular: Title; Abstract; Patients and methods section; p. 5170, 2nd column, 2nd paragraph and table 1. *

DOI:   http://dx.doi.org/10.1200/JCO.2008.20.8934
by applicantWO9954440
 WO2007068354
 WO2011051307
 WO2012146394
 WO2010052013
 WO2010052014
 WO2007131092
 WO2008119567
 WO2008119566
 EP0623679
 WO2004106381
 WO2008119565
   GRUPP ET AL., N. ENGL. J. MED., vol. 368, no. 16, 2013, pages 1509 - 1518
   BUERGER ET AL., JOURNAL OF CLINICAL ONCOLOGY, vol. 21, no. 2, 2003, pages 184 - 188
   BADER ET AL., J. CLIN. ONCOL., vol. 27, 2009, pages 377 - 384
   ECKERT ET AL., LANCET, vol. 358, 2001, pages 1239 - 41
   PORTER ET AL., N ENGL J MED., vol. 365, 2011, pages 725 - 33
   GRUPP ET AL., N ENGL J MED., 2013
   HARLOW; LANE: "Antibodies, A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS
   HARLOW; LANE: "Using Antibodies: A Laboratory Manual", 1999, COLD SPRING HARBOR LABORATORY PRESS
   SKERRA, CURR OPIN BIOTECHNOL., vol. 18, 2007, pages 295 - 304
   HOSSE ET AL., PROTEIN SCI., vol. 15, 2006, pages 14 - 27
   NICAISE ET AL., PROTEIN SCI., vol. 13, 2004, pages 1882 - 91
   NYGREN; UHLN, CURR OPIN STRUCT BIOL., vol. 7, 1997, pages 463 - 9
   KABAT ET AL., SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, 1991
   NEEDLEMAN; WUNSCH, J MOL BIOL., vol. 48, 1970, pages 443 - 53
   SMITH; WATERMAN, ADV APPL MATH., vol. 2, 1981, pages 482 - 9
   WOBBIEJ: "Hypothesis", CRICK. J MOL BIOL., vol. 19, 1966, pages 548 - 55, Retrieved from the Internet
   FARAMARZ NAEIM; P. NAGESH RAO; WAYNE W. GRODY: "Hematopathology", 2008, ELSEVIER
OppositionWO2011051307
 WO2012146394
 WO2014122251
   HUPPMANN ET AL.: "Detection of Leukemic Lymphoblasts in CSF is Instrument- Dependent", AM J CLIN PATHOL, vol. 137, no. 5, 2012, pages 795 - 799, XP055635302

DOI:   http://dx.doi.org/10.1309/AJCPP4HQ2FXQEZIL
   CONTER ET AL.: "Acute Lymphoblastic Leukemia", ORPHANET, December 2004 (2004-12-01), pages 1 - 13, XP055635306, Retrieved from the Internet
   ROBIN T. VOLLMER ET AL.: "Blast Counts in Bone Marrow Aspirate Smears: analysis using the poisson probability function, bayes theorem, and information theory.", AM J CLIN PATHOL, vol. 131, no. 2, 2009, pages 183 - 188, XP055635315 * , ; *

DOI:   http://dx.doi.org/10.1309/AJCPBAYNCU35ZGZG
   AMIN ET AL.: "Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias.", LEUKEMIA, vol. 19, no. 9, 2005, pages 1567 - 1572, XP055397866

DOI:   http://dx.doi.org/10.1038/sj.leu.2403876
   BIANCO ET AL.: "Increased Blasts Mimicking Acute Leukemia in a Patient With Polysubstance Abuse", ARCH PATHOL LAB MED, vol. 129, February 2005 (2005-02-01), pages e35 - e38, XP055635326
   WEINKAUFF ET AL.: "Use of Peripheral Blood Blasts vs Bone Marrow Blasts for Diagnosis of Acute Leukemia", AM J CLIN PATHOL, vol. 111, 1999, pages 733 - 740, XP055524636
   FARAMARZ NAEIM, P. NAGESH RAO AND WAYNE W. GRODY: "HEMATOPATHOLOGY", 2008, ACADEMICPRESS, article FARAMARZ NAEIM: "Chapter 1 - Structure and Function of Hematopoietic Tissues", pages: 1 - 26, XP055635340
   MARIASTEFANIA ANTICA: "Acute Leukemia - The Scientist's Perspective and Challenge", 2011, article ABBAS H. ABDULSALAM: "Diagnosis of Acute Leukemia in Under-Resourced Laboratories", pages: 19 - 40, XP055635347
   AMGEN RESEARCH (MUNICH) GMBH: "Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia", CLINICALTRIALS.GOV, 16 November 2011 (2011-11-16), XP055635351, Retrieved from the Internet
   AMGEN RESEARCH (MUNICH) GMBH: "Study of the BiTE Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)", CLINICALTRIALS.GOV, 27 September 2010 (2010-09-27), XP055635357, Retrieved from the Internet
   AMGEN RESEARCH (MUNICH) GMBH: "Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)", CLINICALTRIALS.GOV, 7 November 2011 (2011-11-07), XP055635360, Retrieved from the Internet
   TOPP ET AL.: "Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival", J CLIN ONCOL, vol. 29, 2011, pages 2493 - 2498, XP055112754

DOI:   http://dx.doi.org/10.1200/JCO.2010.32.7270
   MAURILLO ET AL.: "Treatment of Acute Myeloid Leukemia with 20-30% Bone Marrow Blasts", MEDITERR J HEMATOL INFECT DIS, vol. 5, 2013, pages 1 - 13, XP055635371

DOI:   http://dx.doi.org/10.4084/mjhid.2013.032
   CHING-HON PUI: "Toward Optimal Central Nervous System-Directed Treatment in Childhood Acute Lymphoblastic Leukemia", JOURNAL OF CLINICAL ONCOLOGY, vol. 21, no. 2, 15 January 2003 (2003-01-15), pages 179 - 181, XP055635380

DOI:   http://dx.doi.org/10.1200/JCO.2003.10.032
   BURGER ET AL.: "Diagnostic Cerebrospinal Fluid Examination in Children With Acute Lymphoblastic Leukemia: Significance of Low Leukocyte Counts With Blasts or Traumatic Lumbar Puncture", JOURNAL OF CLINICAL ONCOLOGY, vol. 21, no. 2, 15 January 2003 (2003-01-15), pages 184 - 188, XP055202705

DOI:   http://dx.doi.org/10.1200/JCO.2003.04.096
   CANCELA ET AL.: "Incidence and risk factors for central nervous system relapse in children and adolescents with acute lymphoblastic leukemia", REV BRAS HEMATOL HEMOTER., vol. 34, no. 6, 2012, pages 436 - 441, XP055635389

DOI:   http://dx.doi.org/10.5581/1516-8484.20120109
   JABBOUR ET AL.: "Central Nervous System Prophylaxis in Adults With Acute Lymphoblastic Leukemia", CANCER, vol. 116, no. 10, 2010, pages 2290 - 2300, XP055635397
   PFEIFER ET AL.: "Risk and Prognosis of Central Nervous System Leukemia in Patients with Philadelphia Chromosome-Positive Acute Leukemias Treated with Imatinib Mesylate", CLINICAL CANCER RESEARCH, vol. 9, 15 October 2003 (2003-10-15), pages 4674 - 4681, XP055635488
   HATHAWAY ET AL.: "Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date", PATIENT RELATED OUTCOME MEASURES, vol. 9, 2018, pages 329 - 337, XP055635491

DOI:   http://dx.doi.org/10.2147/PROM.S149420
   DAVIS ET AL.: "Cerebrospinal fluid analysis by flow cytometry in acute lymphoblastic leukemia:is it all that it is cracked up up to be?", LEUKEMIA & LYMPHOMA, vol. 55, no. 7, 2014, pages 1441 - 1443, XP055635497

DOI:   http://dx.doi.org/10.3109/10428194.2013.876499
   LAZARUS ET AL.: "Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993", BLOOD, vol. 108, 2006, pages 465 - 472, XP055635502

DOI:   http://dx.doi.org/10.1182/blood-2005-11-4666
   JABBOUR ET AL.: "Adult Acute Lymphoblastic Leukemia", MAYO CLIN. PROC., vol. 80, no. 11, 2005, pages 1517 - 1527, XP055635506

DOI:   http://dx.doi.org/10.4065/80.11.1517
   MARTINEZ-LAPERCHE ET AL.: "Detection of occult cerebrospinal fluid involvement during maintenance therapy identifies a group of children with acute lymphoblastic leukemia at high risk for relapse", AM. J. HEMATOL., vol. 88, 2013, pages 359 - 364, XP055635522

DOI:   http://dx.doi.org/10.1002/ajh.23407
   ANONYMOUS: "Matter of Record (301) 890-4188", PEDIATRIC ONCOLOGY SUBCOMMITTEE OF THE ONCOLOGIC DRUGS ADVISORY COMMITTEE, 4 December 2012 (2012-12-04), pages 1 - 377
   DIRK NAGORSEN: "Investigation of Blinatumomab in Pediatric Patients with ALL", PRESENTATION, 4 December 2012 (2012-12-04)
   ANONYMOUS: "Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee, Notice of meeting", FEDERAL REGISTER, vol. 77, no. 180, 17 September 2012 (2012-09-17), pages 57095, XP055635533
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.